Company: NCEL
Filing Date: 2025-02-25
Form Type: 425
Source: 0001213900-25-016794
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-02-25
Form: 425
Chunk 4
---
imastem are using forward-looking statements
when they discuss the belief that the results of the pre-IND meeting with the FDA demonstrates the strength of the proposed merger; that
the meeting with the FDA is a significant milestone in the development of iTOL-102, and the expected benefits of iTOL-102 in the treatment
of diabetes. These forward-looking statements and their implications are based on the current expectations of the management of NLS and
Kadimastem and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described
in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described
in the forward-looking statements: risks related to the companies’ ability to complete the merger on the proposed terms and schedule,
including risks and uncertainties related to the satisfaction of the closing conditions related to the merger agreement and risks and
uncertainties related to the failure to timely, or at all, obtain shareholder approvals for the transaction; unexpected costs, charges
or expenses resulting from the transaction and potential adverse reactions or changes to business relationships resulting from the announcement
or completion of the merger; changes in technology and market requirements; either or both companies may encounter delays or obstacles
in launching and/or successfully completing their clinical trials; the companies’ products may not be approved by regulatory agencies;
their technologies may not be validated as they progress and their methods may not be accepted by the scientific community; either of
both of the companies may be unable to retain or attract key employees whose knowledge is essential to the development of their products;
unforeseen scientific difficulties may develop with the products being advanced by the companies; their products may wind up being more
expensive than anticipated; results in the laboratory may not translate to equally good results in real clinical settings; results of
preclinical studies may not correlate with the results of human clinical trials; the companies’ patents may not be sufficient; their
products may harm recipients; changes in legislation may adversely impact either or both of the companies; inability to timely develop
and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition,
which could cause the actual results or performance of candidate products to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, neither Kadimastem nor NLS undertakes any obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the